Marina Peball

Innsbruck Medical University — Austria

Medicine · Health Sciences

15h-index892citations49works2.92yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Parkinson's Disease Mechanisms and Treatments(20), Neurological disorders and treatments(16), Genetic Neurodegenerative Diseases(14), Botulinum Toxin and Related Neurological Disorders(8), Long-Term Effects of COVID-19(6)

Publications47 total

Bridging the gap: sex-specific differences in Huntington’s disease
Orphanet Journal of Rare Diseases·2026Open Access
Simple diameters, accurate stages:a practical approach to HD-ISS staging
Journal of Neurology·2025Open Access
Temporal Muscle Thickness Correlates with Functional Decline in Huntington's Disease
Movement Disorders·2025Open Access
Optical coherence tomography – A possible biomarker in early huntington’s disease
Neurological Research and Practice·2025· 1 citedOpen Access
Silent destruction: hidden muscle wasting and body decline in early Huntington’s disease
Journal of Neural Transmission·2025· 1 citedOpen Access
Neck and mind: exploring emotion processing in cervical dystonia
Frontiers in Neuroscience·2025Open Access
Protocol for olfactory training in persisting COVID-19-associated loss of smell (SMELL): a monocentric randomised controlled trial conducted in Innsbruck
BMJ Open·2025· 1 citedOpen Access
Update on Treatments for Parkinson's Disease Motor Fluctuations – An International Parkinson and Movement Disorder Society Evidence‐Based Medicine Review
Movement Disorders·2025· 32 citedOpen Access
Serum neurofilament light chain but not serum glial fibrillary acidic protein is a marker of early Huntington’s disease
Journal of Neurology·2025Open Access
An unusual presentation of Huntington’s disease-like syndrome in a patient with Xeroderma pigmentosum type F: Case report and review of the literature
Clinical Parkinsonism & Related Disorders·2025Open Access
Objective and subjective cognitive outcomes one year after COVID‐19
Annals of Clinical and Translational Neurology·2024· 1 citedOpen Access
Long‐Term Medication Profiles in Parkinson's Disease under Subthalamic Deep Brain Stimulation: A Controlled Study
Movement Disorders Clinical Practice·2024· 2 citedOpen Access
Sex-related differences in the clinical presentation of multiple system atrophy
Clinical Autonomic Research·2024· 5 citedOpen Access
Serum Neurofilament Light and Clinical Biomarkers for Disease Staging in Huntington's Disease
Movement Disorders Clinical Practice·2024· 1 citedOpen Access
Long-term safety and efficacy of open-label nabilone on sleep and pain in Parkinson´s Disease
npj Parkinson s Disease·2024· 1 citedOpen Access
Distinct smell and taste disorder phenotype of post-acute COVID-19 sequelae
European Archives of Oto-Rhino-Laryngology·2023· 16 citedOpen Access
Body Composition and Physical Performance 1 Year After COVID-19
American Journal of Physical Medicine & Rehabilitation·2023· 5 cited
Pimavanserin: A Truly Effective Treatment for Parkinson’s Disease Psychosis? A Review of Interventions
Neuropsychiatric Disease and Treatment·2023· 10 citedOpen Access
Issue Information
Movement Disorders Clinical Practice·2023· 1 citedOpen Access
Temporal Muscle Thickness Correlates with Sarcopenia in Parkinson’s Disease
Journal of Parkinson s Disease·2023· 15 citedOpen Access
page 1 of 3Next →

Frequent Co-authors

Klaus Seppi(43), Beatrice Heim(34), Atbin Djamshidian(33), Philipp Mahlknecht(18), Werner Poewe(18), Florian Krismer(17), Federico Carbone(16), Philipp Ellmerer(15), Mario Werkmann(10), Dora Valent(9), Stefan Kiechl(8), Gregor K. Wenning(8), Alois Josef Schiefecker(7), Philipp Kindl(7), Judith Löffler‐Ragg(7), Raimund Helbok(7), Verena Rass(6), Ronny Beer(6), Bettina Pfausler(6), Anna Grossauer(6)